86 related articles for article (PubMed ID: 25075093)
1. An NDT study of a boron tracedrug UTX-51 for glycated BSA as an AGE model.
Tada R; Uto Y; Masunaga S; Kinashi Y; Ono K; Hori H
Anticancer Res; 2014 Aug; 34(8):4503-7. PubMed ID: 25075093
[TBL] [Abstract][Full Text] [Related]
2. A neutron dynamic therapy with a boron tracedrug UTX-51 using a compact neutron generator.
Hori H; Tada R; Uto Y; Nakata E; Morii T; Masuda K
Anticancer Res; 2014 Aug; 34(8):4557-60. PubMed ID: 25075099
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and destructive dynamic effects of BODIPY-containing and curcuminoid boron tracedrugs for neutron dynamic therapy.
Nakata E; Koizumi M; Yamashita Y; Onaka K; Sakurai Y; Kondo N; Ono K; Uto Y; Hori H
Anticancer Res; 2011 Jul; 31(7):2477-81. PubMed ID: 21873162
[TBL] [Abstract][Full Text] [Related]
4. Boron tracedrug design for neutron dynamic therapeutics for LDL.
Hori H; Nazumi Y; Uto Y
Adv Exp Med Biol; 2013; 789():385-389. PubMed ID: 23852519
[TBL] [Abstract][Full Text] [Related]
5. Molecular Interaction Between Boron Tracedrug UTX-51 Derivatives and Bovine Serum Albumin: Application to an Analytical Model of AGEs Destruction by Thermal Neutron Irradiation.
Ohkura K; Tabata A; Uto Y; Hori H
Anticancer Res; 2022 Aug; 42(8):4017-4023. PubMed ID: 35896254
[TBL] [Abstract][Full Text] [Related]
6. Boron tracedrugs challenge for neutron dynamic therapy.
Hori H; Uto Y; Nakata E
Anticancer Res; 2012 Jun; 32(6):2235-9. PubMed ID: 22641657
[TBL] [Abstract][Full Text] [Related]
7. Cyclic RGD-Functionalized
Kawai K; Nishimura K; Okada S; Sato S; Suzuki M; Takata T; Nakamura H
Mol Pharm; 2020 Oct; 17(10):3740-3747. PubMed ID: 32845640
[TBL] [Abstract][Full Text] [Related]
8. Maleimide-functionalized closo-dodecaborate albumin conjugates (MID-AC): Unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy.
Kikuchi S; Kanoh D; Sato S; Sakurai Y; Suzuki M; Nakamura H
J Control Release; 2016 Sep; 237():160-7. PubMed ID: 27422608
[TBL] [Abstract][Full Text] [Related]
9. Characterization of anti-advanced glycation end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products.
Choi YG; Lim S
J Immunoassay Immunochem; 2009; 30(4):386-99. PubMed ID: 19739013
[TBL] [Abstract][Full Text] [Related]
10. Advanced-glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway.
Hirasawa Y; Sakai T; Ito M; Yoshimura H; Feng Y; Nagamatsu T
Eur J Pharmacol; 2011 Dec; 672(1-3):159-68. PubMed ID: 21989075
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy.
Mortensen MW; Sørensen PG; Björkdahl O; Jensen MR; Gundersen HJ; Bjørnholm T
Appl Radiat Isot; 2006 Mar; 64(3):315-24. PubMed ID: 16290943
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end product (AGE): characterization of the products from the reaction between D-glucose and serum albumin.
Wu JT; Tu MC; Zhung P
J Clin Lab Anal; 1996; 10(1):21-34. PubMed ID: 8926563
[TBL] [Abstract][Full Text] [Related]
13. Structural Insight Into Protein Binding of Boron Tracedrug UTX-97 Revealed by the Co-Crystal Structure With Lysozyme at 1.26 Å Resolution.
Morimoto Y; Nagasawa H; Uto Y; Chatake T; Hori H
J Pharm Sci; 2016 Aug; 105(8):2298-301. PubMed ID: 27422088
[TBL] [Abstract][Full Text] [Related]
14. In vitro neutron irradiation of glioma and endothelial cultured cells.
Menichetti L; Gaetano L; Zampolli A; Del Turco S; Ferrari C; Bortolussi S; Stella S; Altieri S; Salvadori PA; Cionini L
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S336-40. PubMed ID: 19410472
[TBL] [Abstract][Full Text] [Related]
15. Boron neutron capture therapy in the treatment of locally recurred head and neck cancer.
Kankaanranta L; Seppälä T; Koivunoro H; Saarilahti K; Atula T; Collan J; Salli E; Kortesniemi M; Uusi-Simola J; Mäkitie A; Seppänen M; Minn H; Kotiluoto P; Auterinen I; Savolainen S; Kouri M; Joensuu H
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):475-82. PubMed ID: 17689034
[TBL] [Abstract][Full Text] [Related]
16. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of non-enzymatic thermal glycation of bovine serum albumin (BSA) using β-carotene.
Bodiga VL; Eda SR; Veduruvalasa VD; Mididodla LD; Parise PK; Kodamanchili S; Jallepalli S; Inapurapu SP; Neerukonda M; Vemuri PK; Bodiga S
Int J Biol Macromol; 2013 May; 56():41-8. PubMed ID: 23384487
[TBL] [Abstract][Full Text] [Related]
18. [Boron delivery system for neutron capture therapy of cancer].
Nakamura H
Rinsho Ketsueki; 2008 May; 49(5):294-301. PubMed ID: 18572805
[No Abstract] [Full Text] [Related]
19. Liposome-based delivery of a boron-containing cholesteryl ester for high-LET particle-induced damage of prostate cancer cells: a boron neutron capture therapy study.
Gifford I; Vreeland W; Grdanovska S; Burgett E; Kalinich J; Vergara V; Wang CK; Maimon E; Poster D; Al-Sheikhly M
Int J Radiat Biol; 2014 Jun; 90(6):480-5. PubMed ID: 24605770
[TBL] [Abstract][Full Text] [Related]
20. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase.
Zhang M; Kho AL; Anilkumar N; Chibber R; Pagano PJ; Shah AM; Cave AC
Circulation; 2006 Mar; 113(9):1235-43. PubMed ID: 16505175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
